Proceedings of the 2nd International Conference on Modern Medicine and Global Health
DOI: 10.54254/2753-8818/16/20240592

Analysis of the relationship between Alzheimer's disease and type 2 diabetes

Xinxin Cao

Faculty of Art & Science, University of Toronto, Toronto, ON, Canada, M5R0A3

lucycao0418@gmail.com

Abstract. In recent times, there has been a growing focus in clinical research on the emerging association between Alzheimer's disease (AD) and Type 2 diabetes (T2D). The present study aims to examine the intricate relationship between Type 2 diabetes (T2D) and Alzheimer's disease (AD), shedding light on shared pathophysiological mechanisms and potential therapeutic strategies. This study examines the factors contributing to the observed correlation, with a specific emphasis on vascular dysfunction, inflammation, and insulin resistance. It elucidates the mechanisms by which these shared characteristics influence the progression and manifestation of both diseases. Additionally, this study examines the fundamental mechanisms involved, with a particular focus on the impact of insulin resistance on the accumulation of amyloid-beta, tau protein tangles, and oxidative stress. This study provides valuable insights into the management of Alzheimer's disease (AD) and type 2 diabetes (T2D) by elucidating shared pathways and proposing potential therapeutic approaches, including lifestyle modifications, pharmacological interventions, and glycemic regulation. The importance of preserving cognitive function in individuals with diabetes is emphasized in light of advancing research and therapeutic interventions that demonstrate potential efficacy.

Keywords: Alzheimer's disease, Type 2 diabetes, intervention strategies.

1. Introduction

Within the intricate tapestry of human well-being, a remarkable correlation has emerged, one that intertwines the seemingly disparate realms of Alzheimer's disease (AD) and Type 2 diabetes (T2D), shedding light on the intricate web of our health. In recent times, there has been a growing focus in clinical research on the association between Alzheimer's disease (AD) and Type 2 diabetes (T2D). Both Alzheimer's disease (AD) and type 2 diabetes (T2D) are prevalent chronic conditions that have significant implications for global health. As a result, there has been a growing interest in investigating common underlying mechanisms and potential treatment interventions for these diseases. Alzheimer's disease (AD), a progressive neurodegenerative disorder, has a significant impact on a population of approximately 5.7 million individuals aged 65 and above in the United States. It is projected that the global prevalence of AD will continue to rise and reach a substantial level by the year 2050 [1]. Meanwhile, type 2 diabetes (T2D), characterized by insulin resistance and elevated glucose levels, affected approximately 34.2 million individuals in the United States in 2021, constituting a total estimate of 463 million cases worldwide in 2019 [2]. In recent times, there has been a growing body of research that has revealed an emerging connection between Alzheimer's disease (AD) and Type 2

DOI: 10.54254/2753-8818/16/20240592

diabetes (T2D), both of which are widespread chronic conditions that have a significant impact on the overall health of populations worldwide. Both obesity and hypertension are common risk factors that are shared by these conditions. Research studies suggest that individuals diagnosed with Type 2 Diabetes (T2D) exhibit a 50-100 percent elevated susceptibility to developing Promotion. The aforementioned linkage raises concerns regarding collective systems and potential pathways for therapeutic interventions. The exploration of shared pathways has the potential to significantly advance the management of Alzheimer's disease. The comprehension of this interaction between Alzheimer's disease (AD) and type 2 diabetes (T2D) highlights the necessity for a holistic approach to address these complex health issues. The present clinical research highlights the association between Alzheimer's disease (AD) and Type 2 diabetes (T2D), revealing common pathophysiological factors. This discovery promotes the implementation of integrated strategies to enhance public health outcomes.

This study employed literature analysis and literature review as research methodologies to examine the correlation between T2D and AD. This research extensively examines the intricate interplay and common mechanisms between AD and T2D through the utilization of literature review and analysis techniques. The objective is to advance our comprehension of the relationship between these two conditions.

Consequently, this study investigates the etiological factors such as insulin resistance, inflammation, and vascular dysfunction, elucidating their significance in the pathogenesis of both disorders. The study additionally reveals the influence of insulin resistance on the buildup of amyloid-beta, the formation of tau protein tangles, and the occurrence of oxidative stress, thereby shedding light on the intricate interrelationships. Finally, this discourse delves into prospective interventions encompassing lifestyle modifications, pharmacological interventions, and the regulation of blood glucose levels. These interventions provide valuable perspectives on the management of AD and T2D through common pathways.

However, this study holds significance in other respects. First and foremost, this study contributes to the advancement of research by synthesizing existing knowledge on the association between AD and T2D in a comprehensive manner. This synthesis of literature enhances the comprehension of the shared mechanisms and risk factors involved in these two conditions. Additionally, this study provides practical implications for healthcare practitioners, researchers, and policymakers by proposing viable solutions for the early detection, prevention, and management of both disorders. The holistic approach to public health is emphasized by recognizing the complex association between Alzheimer's disease and type 2 diabetes, hence facilitating the development of more efficacious solutions. Finally, this study provides direction for future research in the field of neurodegenerative and metabolic illnesses, with a particular focus on investigating new therapeutic targets and developing creative medicines that can effectively address both Alzheimer's disease (AD) and type 2 diabetes (T2D).

2. Causes of the Relationship between Alzheimer's disease and Type 2 Diabetes

2.1. Insulin Resistance

Insulin resistance plays a key role in the complex relationship between AD) and T2D, revealing a hidden link. Understanding the link between them requires understanding insulin resistance. Recent investigations show that insulin resistance disrupts cerebral glucose consumption and insulin signaling, causing AD [2]. The study also notes that AD patients often have low brain insulin and receptor levels, which contribute to amyloid plaques and tau tangles. Brain amylin, which is linked to insulin resistance and Type 2 diabetes, varies in sporadic and familial Alzheimer's disease. Animal studies have shown that amylin is involved in AD pathogenesis, suggesting that regulating it may be a therapeutic approach. Thus, Ly et al.'s study highlights the intricate relationship between T2D, brain insulin resistance, and AD, focusing on amylin. Ly et al. posit that Amylin, which is co-secreted alongside insulin [2], exerts an influence on glucose metabolism and exhibits the ability to elevate in instances of insulin dysregulation, hence potentially influencing both blood and brain amylin

DOI: 10.54254/2753-8818/16/20240592

concentrations. An increased concentration of amylin, particularly in the cerebral fluid, has been linked to an elevated risk of Alzheimer's disease, suggesting its involvement in the development of this condition. Despite the presence of regular amylin production in Alzheimer's disease (AD), the interaction between amylin and brain amyloid-beta (Aβ) exacerbates the progression of the illness. Hence, the modulation of insulin secretion and the attenuation of amylin's amyloidogenic characteristics may potentially alleviate this interaction. Therefore, the investigation into familial Alzheimer's disease (AD), cerebrospinal fluid (CSF) analysis, and animal models provides evidence to suggest that amylin could be a promising target for therapeutic interventions, thereby presenting the possibility of developing new treatments for AD.

2.2. Inflammation

Chronic inflammation is a significant common feature observed in both AD and T2D. In the context of T2D, the exacerbation of the condition is triggered by various factors, such as the presence of excessive adipose tissue, particularly visceral fat, and elevated levels of blood glucose, commonly referred to as hyperglycemia. Adipose tissue releases proinflammatory cytokines and adipokines, leading to increased inflammation that is associated with insulin resistance and impaired glucose metabolism [3].The aforementioned phenomenon establishes a cyclical pattern that exacerbates the progression of T2D and its associated problems. Likewise, AD is characterized by persistent inflammation, wherein the immunological response of the brain is mediated by microglia and astrocytes. While the intention behind targeting amyloid plaques and damaged neurons is to address cognitive impairment, this approach may accidentally lead to neuronal damage and cognitive decline as a result of the release of proinflammatory cytokines. There exists a mutual activation of inflammatory pathways in AD and T2D, which contributes to the accelerated course of both illnesses. For example, inflammation associated with T2D has the potential to induce systemic inflammation that can impact the central nervous system. Moreover, insulin resistance, which is a characteristic feature of T2D, is associated with heightened levels of inflammation. The interaction between peripheral and brain inflammation may provide an explanation for the increased risk of AD in individuals withT2D, emphasizing the need for comprehensive anti-inflammatory strategies.

2.3. Vascular Dysfunction

The complex association between T2D and AD becomes apparent due to the presence of common vascular risk factors. The aforementioned disorders are intricately linked, with vascular dysfunction playing a crucial role in connecting them. As an illustration, individuals diagnosed with Type 2 diabetes (T2D) frequently experience hypertension, a condition that adversely affects blood vessels throughout the body, including those in the brain, so impairing the ability to regulate blood flow. According to the findings of Sweeney et al., the brain experiences microvascular alterations that impede the transportation of oxygen and essential nutrients to brain cells. This, in turn, increases the susceptibility to cognitive decline and the development of AD. Moreover, dyslipidemia in T2D perturbs the equilibrium of cholesterol, leading to increased levels of LDL-C and triglycerides, as well as decreased levels of HDL-C [4]. This phenomenon leads to the formation of arterial plaques, often known as atherosclerosis. Atherosclerosis occurring in the cerebral vasculature leads to vasoconstriction and arterial calcification, resulting in reduced blood flow and perhaps contributing to the development of small artery disorders, which impair cognitive function. Moreover, T2D and AD have a common risk factor in the form of atherosclerosis, which impacts both the larger and smaller cerebral blood vessels. Cerebral hypoperfusion occurs as a result of damaged or obstructed cerebral blood vessels, leading to the impairment of essential nutrition delivery to neurons [4]. The continuous reduction in blood flow, known as hypoperfusion, deprives synapses of essential oxygen and nutrients, leading to a decline in their functionality and potentially resulting in cellular demise. This phenomenon is believed to contribute to the progression of Alzheimer's disease. In contrast, the presence of reduced oxygen and nutrient availability in individuals with T2D leads to vascular dysfunction, which subsequently hampers the delivery of oxygen and nutrients to cerebral cells. This

DOI: 10.54254/2753-8818/16/20240592

impairment has a detrimental impact on cognitive processes such as memory and attention [4]. Alzheimer's disease pathology, such as amyloid plaques and tau tangles, can more easily form in brain cells with compromised vascular health. For this reason, the existence of vascular dysfunction, which results from common risk factors in T2D, plays a crucial role in establishing a substantial link between T2D and AD. Therefore, people with type 2 diabetes who investigate and resolve these vascular issues may reduce their risk of developing Alzheimer's disease and preserve their cognitive capacities.

3. Underlying Mechanisms

The presence of amyloid-beta plaques and tau protein tangles characterize the complex landscape of AD, but a new path emerges when we consider the role insulin resistance plays in this pathology.

3.1. Amyloid Beta Accumulation

The protein amyloid-beta has the capacity to undergo misfolding or aggregation, resulting in the formation of plaques within the cerebral region. Insulin resistance, a notable factor in the development of AD, serves as a crucial link between T2D and AD. The digestion and clearance of amyloid-beta (Aβ) in the brain are affected by insulin resistance, a prevalent condition in T2D. Insulin plays a regulatory role in the generation of Aβ within the context of health. Therefore, the dysregulation caused by insulin resistance results in an increase in the synthesis of Aβ, particularly the Aβ42 variant that is prone to aggregation, thereby promoting the formation of plaques. In contrast, insulin facilitates the elimination of Aβ from the brain by augmenting its interaction with receptors on brain capillary endothelial cells and facilitating its transportation across the blood-brain barrier [6]. Insulin resistance hinders the aforementioned process, leading to the accumulation of Aβ and subsequently promoting the formation of plaques. In addition, the presence of insulin resistance initiates neuroinflammation, hence intensifying the detrimental effects associated with Aβ. The activation of microglia and astrocytes during inflammatory responses exacerbates neuronal damage and contributes to the formation of plaques. Hence, insulin resistance facilitates the accumulation of Aβ and the production of plaques, which are crucial characteristics of Alzheimer's disease. The management of insulin resistance is of paramount importance in the context of diabetes and holds potential for ameliorating Alzheimer's disease.

3.2. Tau Protein Tangles and Insulin Signaling

Because tau protein tangles play such a critical part in AD, understanding the connection between T2D and AD can be challenging. In the brain, tau proteins are essential for microtubule stability and, by extension, proper neuronal operation. However, when these proteins are hyperphosphorylated, they change from friendly to hostile, leading to the production of neurofibrillary tangles, which are diagnostic of AD. Nevertheless, the intriguing aspect is in the participation of insulin signaling, a pivotal element of insulin resistance, a characteristic feature of T2D, in the regulation of tau phosphorylation. Insulin signaling plays a crucial role in the maintenance of tau protein phosphorylation equilibrium by regulating the actions of kinases and phosphatases. The enzymatic activity involved in the regulation of phosphorylation and dephosphorylation events on tau proteins is responsible for the control of phosphate group addition and removal. However, the delicate equilibrium is disrupted when insulin resistance arises. The disruption of enzyme control is facilitated by impaired insulin signaling, which subsequently leads to the promotion of tau hyperphosphorylation. As a result, tau proteins undergo aggregation, forming neurofibrillary tangles, which subsequently hinder the functioning of neurons and play a role in the decrease of cognitive abilities observed in Alzheimer's disease. The offered source highlights the complexities of the link between AD and T2D, namely how defects in insulin signaling contribute to the formation of the characteristic tau pathology seen in AD as well as the metabolism of amyloid-beta. The foregoing findings emphasize the importance of establishing holistic methods that address both T2D and AD, taking into account the shared processes and potential therapy targets between the two conditions.

DOI: 10.54254/2753-8818/16/20240592

3.3. Oxidative Stress

T2D and AD are linked in many ways, and oxidative stress is a key mediator of these relationships. Hyperglycemia, a feature of T2D, is associated with an uptick in ROS production [7], including superoxide radicals and hydrogen peroxide. Reactive oxygen species (ROS) are created when molecular oxygen undergoes a chemical reaction with hyperglycemia. These microscopic agents possess a strong inclination to attack cellular components. However, their detrimental trajectory extends beyond the scope of diabetes, posing a threat to brain health. In the context of the brain, neurons are particularly susceptible to damage caused by reactive oxygen species (ROS). Therefore, oxidative stress has been discovered to damage lipids, proteins, and nucleic acids, leading to cellular dysfunction and possible cell death, as demonstrated by the study conducted by Robertson et al. Significantly, within the context of AD, oxidative stress has a crucial role in promoting the buildup of amyloid-beta plaques and the creation of tau protein tangles, which are hallmark characteristics of the disease. The detrimental impact of oxidative stress extends beyond T2D, infiltrating the complex interconnection between T2D and AD. The detrimental effects of reactive oxygen species (ROS) on brain cells not only contribute to cognitive loss, but also create a favorable environment for the development of AD pathology. Oxidative stress serves as a common element that contributes to the exacerbation of the interplay between these intricate circumstances. The convergence of oxidative stress highlights the critical need for comprehensive therapies that effectively target both diseases. People with type 2 diabetes may be able to reduce their chance of developing Alzheimer's disease and slow the disease's progression by making lifestyle changes, using antioxidant medications, or engaging in other interventions that reduce oxidative stress. This method emphasizes the need for all-encompassing approaches to overcoming these formidable obstacles.

3.4. Impaired Brain Insulin Signaling

Damaged insulin transmission in the brain is a hallmark of type 2 diabetes. Insulin is essential for regulating synaptic plasticity in the brain in addition to its role in glucose metabolism. But in the context of T2D, insulin resistance in the periphery often exerts an effect on the central nervous system as well. T2D is characterized by insulin resistance, which manifests itself in decreased brain cell response to insulin signaling [8]. This phenomenon not only hinders the process of glucose uptake, but also affects the synaptic plasticity of the brain, which refers to its ability to adjust and enhance neural connections. As a result, there may be a decline in memory formation and cognitive function. There is a notable association between cognitive deterioration and T2D. The cognitive problems in this condition are further intensified by the brain's state of insulin deprivation. The aforementioned dual impact highlights the necessity of implementing comprehensive therapies that effectively tackle both the metabolic and cognitive dimensions of Type 2 Diabetes (T2D). Consequently, the compromised signaling of insulin in the brain in individuals with type 2 diabetes (T2D) establishes a significant connection to Alzheimer's disease (AD) through common characteristics. Therefore, it is imperative to prioritize the maintenance of brain health in individuals with T2D in order to effectively combat the increasing prevalence of AD. Acknowledging the need of sustaining cognitive function in the context of diabetes is of utmost importance, given the extensive incidence of this disorder.

4. Interventions

4.1. Lifestyle Modifications

In the context of combating both Type 2 diabetes (T2D) and Alzheimer's disease (AD), a combination of three lifestyle modifications, namely adopting a nutritious diet, engaging in consistent physical activity, and effectively managing body weight, assumes a prominent role in promoting improved overall well-being. The maintenance of metabolic and cognitive well-being is greatly influenced by the adoption of a balanced diet, regular exercise, and effective weight control. These actions serve to manage blood sugar levels, enhance insulin sensitivity, and counteract inflammation, which is a frequently encountered challenge. Diets such as the Mediterranean or DASH patterns exhibit potential

DOI: 10.54254/2753-8818/16/20240592

in combating Alzheimer's disease [9]. Physical activity improves insulin sensitivity, which is particularly important in those with T2D, and promotes the maintenance of healthy blood vessels in the brain, leading to cognitive benefits. The process of losing excessive weight has been found to have a positive impact on insulin sensitivity and vascular health, hence reducing the risk of atherosclerosis. These principles represent more than simple abstract concepts; rather, they encompass practical measures that can be taken to promote improved well-being.

4.2. Pharmacological Treatments

Conventionally viewed as independent diseases, T2D and AD have a complicated interaction that may be addressed with pharmacological therapies. Metformin is an essential part of treatment for type 2 diabetes, and there is promising evidence that it can also treat Alzheimer's disease [10]. Despite its primary function—to control blood sugar and boost insulin sensitivity—metformin displays pleiotropic effects that are relevant to AD. Researchers have found some indication that it may slow the mental loss seen in Alzheimer's disease patients. Its capacity to reduce inflammation, increase mitochondrial function, and boost insulin signaling—all of which have been implicated in AD—may explain this result. The discovery of dual-action medicines that attack insulin resistance and AD pathogenesis at the same time is another emerging field of study [11]. These innovative medications show that researchers have figured out the intricate web of connections between type 2 diabetes and Alzheimer's disease, and they provide solutions that tackle insulin resistance and AD's distinctive features including amyloid-beta plaque development and tau protein tangles. Pharmacological therapies may serve as a link between type 2 diabetes and Alzheimer's disease, highlighting the need for ongoing study and pharmaceutical development. As the incidence of these diseases continues to rise, it is critical that we find strategies to treat them effectively by focusing on their shared underlying mechanisms. The ever-evolving area of pharmacology offers exciting new possibilities for the treatment of T2D and AD, including the potential to slow or halt their deterioration. Those suffering from these devastating diseases can look to the future with newfound optimism because to this breakthrough.

4.3. Blood Sugar Control

Keeping blood sugar levels under control is essential in the treatment of T2D and may help reduce the risk of AD. The maintenance of normal blood glucose levels is the goal of a number of treatments [12]. These include the use of medications, insulin therapy, and careful dietary management. It has been suggested that controlling blood sugar levels, in addition to managing type 2 diabetes, may reduce the incidence of AD by reducing inflammation and oxidative stress, two common risk factors. Glycemic equilibrium can be restored with effective management of T2D by maintaining tight control of blood sugar levels. The risk of complications like cardiovascular disease and nerve damage can be reduced with the help of medications like metformin, which improve insulin sensitivity. However, it's crucial to remember the importance of preventing AD, since recent studies suggest that keeping blood glucose levels in check may reduce the risk of developing AD. It is well established that elevated blood glucose levels play a crucial role in fostering inflammation and fostering the development of vascular damage in AD. However, extreme care must be used while introducing new control mechanisms to reduce the possibility of hypoglycemia. The prevention of type 2 diabetes and Alzheimer's disease relies heavily on the regular monitoring of blood sugar levels.

5. Conclusion

T2D and AD exhibit a complex interrelationship due to shared risk factors, underlying mechanisms, and clinical manifestations. Vascular dysfunction, insulin resistance, and chronic inflammation are interrelated factors that accelerate the progression of these disorders. This complicated interplay is underscored by mechanisms such as amyloid-beta buildup, tau protein tangles, oxidative stress, and altered brain insulin signaling. However, there is a glimmer of hope in the form of lifestyle adjustments, pharmaceutical interventions such as metformin, and effective management of blood

DOI: 10.54254/2753-8818/16/20240592

sugar levels. These approaches present promising opportunities to alter the trajectory of both conditions. Understanding the significance of sustaining brain health in the context of diabetes is of utmost relevance, particularly given the increasing prevalence of T2D and AD. The ongoing advancements in research and therapeutic approaches offer potential benefits for individuals impacted by the subject matter, underscoring the importance of further elucidating their complex interrelationship and devising efficacious remedies. Hence, the current medical study on AD and T2D highlights a significant association, indicating comparable pathophysiological pathways. Consequently, this emphasizes the need for coordinated solutions to enhance public health outcomes.

References

[1] Ly, H., Verma, N., Sharma, S., Kotiya, D., Despa, S., Abner, E. L., ... & Despa, F. (2021). The association of circulating amylin with β-amyloid in familial Alzheimer's disease. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 7(1), e12130.

[2] Derrick, S. A., Kristo, A. S., Reaves, S. K., & Sikalidis, A. K. (2021). Effects of dietary red raspberry consumption on pre-diabetes and type 2 diabetes mellitus parameters. International Journal of Environmental Research and Public Health, 18(17), 9364.

[3] Kojta, I., Chacińska, M., & Błachnio-Zabielska, A. (2020). Obesity, bioactive lipids, and adipose tissue inflammation in insulin resistance. Nutrients, 12(5), 1305.

[4] Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018). Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nature Reviews Neurology, 14(3), 133-150.

[5] de la Torre, J. C. (2012). Cerebral hemodynamics and vascular risk factors: setting the stage for Alzheimer's disease. Journal of Alzheimer's Disease, 32(3), 553-567.

[6] Rhea, E. M., & Banks, W. A. (2019). Role of the blood-brain barrier in central nervous system insulin resistance. Frontiers in neuroscience, 13, 521.

[7] Robertson, R. P., Harmon, J., Tran, P. O., Tanaka, Y., & Takahashi, H. (2003). Glucose toxicity in β-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes, 52(3), 581-587.

[8] Kullmann, S., Heni, M., Hallschmid, M., Fritsche, A., Preissl, H., & Häring, H. U. (2016). Brain insulin resistance at the crossroads of metabolic and cognitive disorders in humans. Physiological reviews.

[9] Burini, R. C., Anderson, E., Durstine, J. L., & Carson, J. A. (2020). Inflammation, physical activity, and chronic disease: An evolutionary perspective. Sports Medicine and Health Science, 2(1), 1-6.

[10] Bonnet, F., & Scheen, A. (2017). Understanding and overcoming metformin gastrointestinal intolerance. Diabetes, Obesity and Metabolism, 19(4), 473-481.

[11] Moussa, N., & Dayoub, N. (2023). Exploring the role of COX-2 in Alzheimer's disease: Potential therapeutic implications of COX-2 inhibitors. Saudi Pharmaceutical Journal, 101729.

[12] Holt, R. I., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., ... & Peters, A. L. (2021). The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes care, 44(11), 2589-2625.